Advertisement

Hereditary or Not? Understanding Serrated Polyposis Syndrome

  • Peter P. StanichEmail author
  • Rachel Pearlman
Genetics in Gastroenterology Practice (B Katona, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Genetics in Gastroenterology Practice

Abstract

Purpose of review

To present the current understanding of the diagnosis, management, and potential genetic causes of serrated polyposis syndrome.

Recent findings

The clinical criteria for serrated polyposis syndrome was recently updated and now includes individuals with five or more serrated polyps proximal to the rectum that are 5 mm in size or greater and at least two that are 10 mm in size of greater as well as individuals with 20 or more serrated polyps throughout the colon with at least five proximal to the rectum. There is a significant risk for colon cancer in first-degree relatives of individuals with serrated polyposis syndrome. However, less than 3% of serrated polyposis syndrome cases are explained by identifiable germline mutations, with mutations in RNF43 being the only currently validated genetic cause.

Summary

Serrated polyposis syndrome is rarely explained by identifiable germline mutations, but there remains an increased risk for colorectal cancer in first-degree relatives. Referral for genetic counseling and testing is recommended for individuals with serrated polyposis syndrome and a personal history of coexisting adenomatous polyposis or with a concerning family history and can be considered for all individuals with serrated polyposis syndrome. Close endoscopic surveillance of those with serrated polyposis syndrome and their first-degree relatives is recommended. Continued efforts at identifying hereditary causes of serrated polyposis are needed.

Keywords

Colonic polyps Human Genetics Hyperplastic polyposis syndrome Serrated polyposis syndrome 

Notes

Compliance with Ethical Standards

Conflict of Interest

PPS has performed collaborative research with Ambry Genetics. RP has performed collaborative research with Ambry Genetics, Myriad Genetics Laboratories, Inc, and InVitae Genetics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:• Of importance ••Of major importance

  1. 1.
    Snover DC, Ahnen DJ, Burt RW, Odze RD. Serrated polyps of the colon and rectum and serrated polyposis. In: Bozman FT, Carneiro F, Hruban RH, Theise N, editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 160–5.Google Scholar
  2. 2.
    Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107(9):1315–29 ;quiz 4, 30.  https://doi.org/10.1038/ajg.2012.161.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003;27(1):65–81.CrossRefGoogle Scholar
  4. 4.
    Hiraoka S, Kato J, Fujiki S, Kaji E, Morikawa T, Murakami T, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology. 2010;139(5):1503–10; 10 e1-3.  https://doi.org/10.1053/j.gastro.2010.07.011.CrossRefGoogle Scholar
  5. 5.
    Gao Q, Tsoi KK, Hirai HW, Wong MC, Chan FK, Wu JC, et al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(4):501–9; quiz 10.  https://doi.org/10.1038/ajg.2015.49.CrossRefGoogle Scholar
  6. 6.
    Erichsen R, Baron JA, Hamilton-Dutoit SJ, Snover DC, Torlakovic EE, Pedersen L, et al. Increased risk of colorectal cancer development among patients with serrated polyps. Gastroenterology. 2016;150(4):895–902 e5.  https://doi.org/10.1053/j.gastro.2015.11.046.CrossRefGoogle Scholar
  7. 7.
    Abdeljawad K, Vemulapalli KC, Kahi CJ, Cummings OW, Snover DC, Rex DK. Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist. Gastrointest Endosc. 2015;81(3):517–24.  https://doi.org/10.1016/j.gie.2014.04.064.CrossRefPubMedGoogle Scholar
  8. 8.
    Shaukat A, Gravely AA, Kim AS, Rank J, Church TR, Allen JI. Rates of detection of adenoma, sessile serrated adenoma, and advanced adenoma are stable over time and modifiable. Gastroenterology. 2019;156(3):816–7.  https://doi.org/10.1053/j.gastro.2018.10.052.CrossRefPubMedGoogle Scholar
  9. 9.
    Jeevaratnam P, Cottier DS, Browett PJ, Van De Water NS, Pokos V, Jass JR. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol. 1996;179(1):20–5.  https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<20::AID-PATH538>3.0.CO;2-C.CrossRefGoogle Scholar
  10. 10.
    Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology. 1996;110(3):748–55.  https://doi.org/10.1053/gast.1996.v110.pm8608884.CrossRefPubMedGoogle Scholar
  11. 11.
    Jass JR, Cottier DS, Pokos V, Parry S, Winship IM. Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis. Pathology. 1997;29(1):28–33.CrossRefGoogle Scholar
  12. 12.
    Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol. 2001;25(2):177–84.CrossRefGoogle Scholar
  13. 13.
    Yeoman A, Young J, Arnold J, Jass J, Parry S. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. N Z Med J. 2007;120(1266):U2827.PubMedGoogle Scholar
  14. 14.
    Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010;59(8):1094–100.  https://doi.org/10.1136/gut.2009.185884.CrossRefGoogle Scholar
  15. 15.
    Carballal S, Rodriguez-Alcalde D, Moreira L, Hernandez L, Rodriguez L, Rodriguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2016;65(11):1829–37.  https://doi.org/10.1136/gutjnl-2015-309647.CrossRefPubMedGoogle Scholar
  16. 16.
    Burt R, Jass JR. Hyperplastic polyposis. In: Hamilton S, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2000. p. 135–6.Google Scholar
  17. 17.
    van Herwaarden YJ, Verstegen MH, Dura P, Kievit W, Drenth JP, Dekker E, et al. Low prevalence of serrated polyposis syndrome in screening populations: a systematic review. Endoscopy. 2015;47(11):1043–9.  https://doi.org/10.1055/s-0034-1392411.CrossRefGoogle Scholar
  18. 18.
    • IJspeert JEG, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. Gut. 2017;66(7):1225–32.  https://doi.org/10.1136/gutjnl-2015-310784 Provided updated prevalence rates for serrated polyposis syndrome and showed that previous reports were likely underestimates.CrossRefPubMedGoogle Scholar
  19. 19.
    Biswas S, Ellis AJ, Guy R, Savage H, Madronal K, East JE. High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme. Gut. 2013;62(3):475.  https://doi.org/10.1136/gutjnl-2012-303233.CrossRefPubMedGoogle Scholar
  20. 20.
    Moreira L, Pellise M, Carballal S, Bessa X, Ocana T, Serradesanferm A, et al. High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. Gut. 2013;62(3):476–7.  https://doi.org/10.1136/gutjnl-2012-303496.CrossRefPubMedGoogle Scholar
  21. 21.
    Colussi D, Zagari RM, Morini B, Fabbri M, Montale A, Hassan C, et al. Prevalence of serrated polyposis syndrome in an FIT-based colorectal cancer screening cohort in Italy. Gut. 2017;66(8):1532–3.  https://doi.org/10.1136/gutjnl-2016-313063.CrossRefPubMedGoogle Scholar
  22. 22.
    IJspeert JEG, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2017;66(2):278–84.  https://doi.org/10.1136/gutjnl-2015-310630.CrossRefPubMedGoogle Scholar
  23. 23.
    Young J, Jass JR. The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol Biomark Prev. 2006;15(10):1778–84.  https://doi.org/10.1158/1055-9965.EPI-06-0164.CrossRefGoogle Scholar
  24. 24.
    Young J, Jenkins M, Parry S, Young B, Nancarrow D, English D, et al. Serrated pathway colorectal cancer in the population: genetic consideration. Gut. 2007;56(10):1453–9.  https://doi.org/10.1136/gut.2007.126870.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lanspa SJ, Ahnen DJ, Lynch HT. Serrated polyposis: the last (or only the latest?) frontier of familial polyposis? Am J Gastroenterol. 2012;107(5):779–81.  https://doi.org/10.1038/ajg.2012.62.CrossRefPubMedGoogle Scholar
  26. 26.
    •• Rosty C, Brosens LAA, Dekker E, Nagtegaal ID. Serrated polyposis. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. WHO classification of tumours: digestive system tumours. Lyon: International Agency for Research on Cancer; 2019. p. 532–4. A major update to the serrated polyposis syndrome diagnostic criteria was introduced in this internationally referenced text.Google Scholar
  27. 27.
    Jass JR. Gastrointestinal polyposes: clinical, pathological and molecular features. Gastroenterol Clin N Am. 2007;36(4):927–46, viii.  https://doi.org/10.1016/j.gtc.2007.08.009.CrossRefGoogle Scholar
  28. 28.
    Terradas M, Munoz-Torres PM, Belhadj S, Aiza G, Navarro M, Brunet J, et al. Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1- and MSH3-associated polyposes. Hum Mutat. 2019.  https://doi.org/10.1002/humu.23853.CrossRefGoogle Scholar
  29. 29.
    Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146(2):520–9.  https://doi.org/10.1053/j.gastro.2013.10.045.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Taupin D, Lam W, Rangiah D, McCallum L, Whittle B, Zhang Y, et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. Hum Genome Var. 2015;2:15013.  https://doi.org/10.1038/hgv.2015.13.
  31. 31.
    •• Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2017;66(9):1645–56.  https://doi.org/10.1136/gutjnl-2016-311849 Validated link between RNF43 and serrated polyposis syndrome by confirming the second-hit inactivation of the gene in serrated polyps and tumor of affected patients.CrossRefGoogle Scholar
  32. 32.
    • Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. Gut. 2017;66(6):1170–2.  https://doi.org/10.1136/gutjnl-2016-312773 Analyzed RNF43 in the largest cohort of serrated polyposis patients to date and showed that only 2/295 (0.7%) had pathogenic variants.CrossRefGoogle Scholar
  33. 33.
    Quintana I, Mejias-Luque R, Terradas M, Navarro M, Pinol V, Mur P, et al. Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut. 2018;67(12):2230–2.  https://doi.org/10.1136/gutjnl-2017-315733.CrossRefPubMedGoogle Scholar
  34. 34.
    Kokko A, Laiho P, Lehtonen R, Korja S, Carvajal-Carmona LG, Jarvinen H, et al. EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer. 2006;6:145.  https://doi.org/10.1186/1471-2407-6-145.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, Hodgkin L, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology. 2006;131(1):30–9.  https://doi.org/10.1053/j.gastro.2006.03.046.CrossRefGoogle Scholar
  36. 36.
    Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008;135(6):2014–8.  https://doi.org/10.1053/j.gastro.2008.09.020.CrossRefPubMedGoogle Scholar
  37. 37.
    Guarinos C, Juarez M, Egoavil C, Rodriguez-Soler M, Perez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20(5):1158–68.  https://doi.org/10.1158/1078-0432.CCR-13-1490.CrossRefPubMedGoogle Scholar
  38. 38.
    Clendenning M, Young JP, Walsh MD, Woodall S, Arnold J, Jenkins M, et al. Germline mutations in the polyposis-associated genes BMPR1A, SMAD4, PTEN, MUTYH and GREM1 are not common in individuals with serrated polyposis syndrome. PLoS One. 2013;8(6):e66705.  https://doi.org/10.1371/journal.pone.0066705.CrossRefGoogle Scholar
  39. 39.
    Petronio M, Pinson S, Walter T, Joly MO, Hervieu V, Forestier J, et al. Type 1 serrated polyposis represents a predominantly female disease with a high prevalence of dysplastic serrated adenomas, without germline mutation in MUTYH, APC, and PTEN genes. United European Gastroenterol J. 2016;4(2):305–13.  https://doi.org/10.1177/2050640615594939.CrossRefGoogle Scholar
  40. 40.
    Andersen SH, Lykke E, Folker MB, Bernstein I, Holck S. Sessile serrated polyps of the colorectum are rare in patients with Lynch syndrome and in familial colorectal cancer families. Familial Cancer. 2008;7(2):157–62.  https://doi.org/10.1007/s10689-007-9163-7.CrossRefPubMedGoogle Scholar
  41. 41.
    Vleugels JLA, Sahin H, Hazewinkel Y, Koens L, van den Berg JG, van Leerdam ME, et al. Endoscopic detection rate of sessile serrated lesions in Lynch syndrome patients is comparable with an age- and gender-matched control population: case-control study with expert pathology review. Gastrointest Endosc. 2018;87(5):1289–96.  https://doi.org/10.1016/j.gie.2017.11.034.CrossRefGoogle Scholar
  42. 42.
    Jasperson KW, Kanth P, Kirchhoff AC, Huismann D, Gammon A, Kohlmann W, et al. Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis Colon Rectum. 2013;56(11):1211–6.  https://doi.org/10.1097/DCR.0b013e3182a11cca.CrossRefPubMedGoogle Scholar
  43. 43.
    Jarrar AM, Church JM, Fay S, Kalady MF. Is the phenotype mixed or mistaken? Hereditary nonpolyposis colorectal cancer and hyperplastic polyposis syndrome. Dis Colon Rectum. 2009;52(12):1949–55.  https://doi.org/10.1007/DCR.0b013e3181b5450c.CrossRefPubMedGoogle Scholar
  44. 44.
    Boparai KS, Reitsma JB, Lemmens V, van Os TA, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59(9):1222–5.  https://doi.org/10.1136/gut.2009.200741.CrossRefGoogle Scholar
  45. 45.
    Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107(5):770–8.  https://doi.org/10.1038/ajg.2012.52.CrossRefGoogle Scholar
  46. 46.
    Hazewinkel Y, Reitsma JB, Nagengast FM, Vasen HF, van Os TA, van Leerdam ME, et al. Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives. Familial Cancer. 2013;12(4):669–73.  https://doi.org/10.1007/s10689-013-9643-x.CrossRefGoogle Scholar
  47. 47.
    Kalady MF, Jarrar A, Leach B, LaGuardia L, O'Malley M, Eng C, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum. 2011;54(2):164–70.  https://doi.org/10.1007/DCR.0b013e3181fd4c15.CrossRefGoogle Scholar
  48. 48.
    • Egoavil C, Juarez M, Guarinos C, Rodriguez-Soler M, Hernandez-Illan E, Alenda C, et al. Increased risk of colorectal cancer in patients with multiple serrated polyps and their first-degree relatives. Gastroenterology. 2017;153(1):106–12 e2. Increased risk for colorectal cancer was seen in close relatives of serrated polyposis patients but also in relatives of those with multiple serrated polyps not meeting WHO criteria for serrated polyposis syndrome. This suggests WHO criteria still need optimization to capture individuals and family members at increased risk.  https://doi.org/10.1053/j.gastro.2017.04.003.CrossRefGoogle Scholar
  49. 49.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 63.  https://doi.org/10.1038/ajg.2014.435.CrossRefGoogle Scholar
  50. 50.
    National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2019 ed2019.Google Scholar
  51. 51.
    Bleijenberg AG, IJspeert JEG, van Herwaarden YJ, Carballal S, Pellise M, Jung G, et al. Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut. 2019.  https://doi.org/10.1136/gutjnl-2018-318134.
  52. 52.
    MacPhail ME, Thygesen SB, Patel N, Broadley HM, Rex DK. Endoscopic control of polyp burden and expansion of surveillance intervals in serrated polyposis syndrome. Gastrointest Endosc. 2019;90(1):96–100.  https://doi.org/10.1016/j.gie.2018.11.016.CrossRefPubMedGoogle Scholar
  53. 53.
    Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. Guideline Development Group ACoMG et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87.  https://doi.org/10.1038/gim.2014.147.CrossRefPubMedGoogle Scholar
  54. 54.
    Hassan C, Quintero E, Dumonceau JM, Regula J, Brandao C, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2013;45(10):842–51.  https://doi.org/10.1055/s-0033-1344548.CrossRefPubMedGoogle Scholar
  55. 55.
    Hazewinkel Y, Koornstra JJ, Boparai KS, van Os TA, Tytgat KM, Van Eeden S, et al. Yield of screening colonoscopy in first-degree relatives of patients with serrated polyposis syndrome. J Clin Gastroenterol. 2015;49(5):407–12.  https://doi.org/10.1097/MCG.0000000000000103.CrossRefPubMedGoogle Scholar
  56. 56.
    Oquinena S, Guerra A, Pueyo A, Eguaras J, Montes M, Razquin S, et al. Serrated polyposis: prospective study of first-degree relatives. Eur J Gastroenterol Hepatol. 2013;25(1):28–32.  https://doi.org/10.1097/MEG.0b013e3283598506.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology & NutritionThe Ohio State University Wexner Medical CenterColumbusUSA
  2. 2.Division of Human GeneticsThe Ohio State University Comprehensive Cancer CenterColumbusUSA

Personalised recommendations